What the FDA labels say about taking them together
Golimumab and theophylline
Golimumab's FDA label of September 9, 2025 names theophylline in its drug interactions section; the theophylline label PlainMeds reads does not name golimumab. The golimumab label: “Upon initiation or discontinuation of SIMPONI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration is recommended and the …”
Check it at the source: the golimumab FDA label on DailyMed (effective September 9, 2025, Janssen Biotech, Inc.); the theophylline FDA label on DailyMed (effective March 10, 2026, Strides Pharma Science Limited).
What does the golimumab label say about theophylline?
Golimumab label, drug interactionsUpon initiation or discontinuation of SIMPONI ARIA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
Source: FDA drug label (Simponi, BLA125289), Janssen Biotech, Inc., effective October 29, 2025 (SPL set f86cb4a7-c358-4136-ae57-b32bda9bba00), via openFDA
Source: FDA drug label (SIMPONI ARIA), Janssen Biotech, Inc., effective September 9, 2025 (SPL set 9e260a47-55af-4c92-8d88-a86ccc767fff), via openFDA; the full label on DailyMed
What does the theophylline label say about golimumab?
Theophylline's label (effective March 10, 2026) does not name golimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Theophylline), Strides Pharma Science Limited, effective March 10, 2026 (SPL set b7a90ccf-9c32-40cc-9008-7e55b3da4dfd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Golimumab | Theophylline | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | Asthma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $12,890.32 per mL 50 mg/0.5 mL pen injec | $0.330 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once